Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib Plus Chemotherapy vs Osimertinib in EGFR-Mutated NSCLC With Brain Metastases
NCT06970639Phase 3Recruiting
- Sponsor
- Allist Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Allist Pharmaceuticals. Primary endpoints: Adverse Events up to 4 years, Serious Adverse Events up to 4 years and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06970639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970639.